Entresto 97 mg+103 mg (Tablet)
Unit Price: ৳ 134.00 (6 x 10: ৳ 8,040.00)
Strip Price: ৳ 1,340.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Novartis bangladesh ltd |
| Also available as |
Indications
- Reduce the risk of cardiovascular death
- Reduce hospitalization for heart failure
- Treatment of symptomatic heart failure
- Administered in conjunction with other heart failure therapies
Pharmacology
- Contains neprilysin inhibitor, sacubitril
- Contains angiotensin receptor blocker, valsartan
- Inhibits neprilysin and blocks angiotensin II type-1 receptor
- Effects attributed to increased levels of peptides degraded by neprilysin
Dosage & Administration
- Recommended starting dose for adult heart failure
- Double the dose after 2 to 4 weeks
- Reduce starting dose for patients not currently taking ACEi or ARB
- Recommended dose titration for pediatric patients
Interaction
- Should not be used with ACEi, aliskiren in patients with diabetes
- Avoid use with ARB
- Potential increase in serum potassium level with potassium-sparing diuretics
- Risk of renal impairment increased with NSAIDs
- Increased risk of lithium toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired Renal Function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required in patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
Precautions & Warnings
- May cause angioedema
- Lowers blood pressure and may cause symptomatic hypotension
- Closely monitor serum creatinine
- Monitor serum potassium periodically
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients
- Starting dose adjustment recommended for severe renal impairment
- Starting dose adjustment recommended for moderate hepatic impairment
- Use not recommended in patients with severe hepatic impairment
Overdose Effects
- Hypotension likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children